iBio, Inc. Form 10-Q Summary
Business Context and Reporting Period
iBio, Inc. is a biotechnology company commercializing plant-based protein expression technologies, including the iBioLaunch™ platform for vaccines and therapeutic proteins and the iBioModulator™ platform for vaccine enhancement. The company also develops selected product candidates and seeks licensing, collaboration, and partnering arrangements.
This unaudited Form 10-Q covers the three months ended September 30, 2013, the first quarter of fiscal 2014. Operations and assets are located exclusively in the United States. A wholly owned subsidiary, iBioDefense Biologics LLC, was formed in July 2013 but had no activity through September 30, 2013.
Financial Results and Key Metrics
| Metric | Three Months Ended September 30, 2013 | Three Months Ended September 30, 2012 |
|---|---|---|
| Revenue | $0 | $390,000 |
| Operating income (loss) | $240,000 | $(1.81) million |
| Net income (loss) | $379,000 | $(2.051) million |
| Basic earnings (loss) per share | $0.01 | $(0.04) |
| Net cash used in operating activities | $911,000 | $1.290 million |
| Net cash used in investing activities | $59,000 | $58,000 |
- Gross margin and revenue-based margins were not meaningful because the company reported no revenue in the current quarter.
- Research and development expense was a credit of $501,000, including a $1.041 million benefit from the Fraunhofer settlement. Excluding that benefit, current-quarter research and development spending was approximately $540,000.
- General and administrative expense was $249,000, including a $700,000 settlement-related credit. Excluding the credit, spending was approximately $949,000.
- Other income was approximately $139,000, including a $122,000 reversal of accrued interest expense under the prior Fraunhofer agreement.
- Share-based compensation expense was $235,000, compared with $454,000 in the prior-year quarter.
- Cash declined from $4.414 million at June 30, 2013 to $3.444 million at September 30, 2013. Total current assets were $4.645 million and total current liabilities were $1.653 million.
- Total assets were $7.335 million, total liabilities were $1.653 million, and stockholders’ equity was $5.682 million at September 30, 2013.
- Accumulated deficit was approximately $37.2 million. The company had no debt balance reported, although certain historical amounts owed to Fraunhofer were addressed through the settlement agreement.
Material Changes Versus the Prior Comparable Period
- Revenue fell to zero from $390,000. Prior-year revenue related to technology services for FioCruz’s yellow fever vaccine program; revenue recognition was suspended while the parties awaited Brazilian government approval of a contract amendment.
- The company reported net income of $379,000 versus a $2.051 million net loss, primarily because of the Fraunhofer settlement credits and lower operating spending.
- Operating cash burn improved to $911,000 from $1.290 million, but operations continued to consume cash.
- Approximately 5.0 million August 2008 warrants expired in August 2013. The related warrant derivative liability was eliminated, and the prior-year period’s $241,000 non-cash fair-value expense did not recur.
- In September 2013, the Fraunhofer settlement released approximately $2.9 million of company liabilities outstanding at June 30, 2013. The settlement produced an approximately $1.9 million positive earnings impact, consisting of credits to research and development, general and administrative, and interest expense.
- Following the settlement, the company’s TTA term was extended through December 31, 2015, and minimum annual royalty payments and guaranteed annual payments were eliminated. The company must instead engage Fraunhofer for at least $3 million of research and development work by December 31, 2015.
Liquidity, Outlook, Risks, and Unusual Items
- Management stated that cash on hand at September 30, 2013, together with approximately $3.1 million of subsequent warrant exercise proceeds and $0.5 million of subsequent private-placement proceeds, was expected to fund activities through the quarter ending December 31, 2014.
- The filing continues to state that substantial doubt exists about the company’s ability to continue as a going concern because of its history of losses, negative operating cash flow, limited cash resources, and dependence on additional financing.
- Management expects to fund operations through existing cash, additional equity or other securities, and license or collaboration proceeds. Financing may not be available on favorable terms or at all, and equity financing could materially dilute existing stockholders.
- If additional funding is unavailable, the company may delay, reduce, or discontinue development and commercialization activities, accept less favorable collaborations, relinquish technology or product rights, or potentially cease operations.
- As of September 30, 2013, Fraunhofer-related research service agreements represented approximately $1.8 million of the required $3 million commitment; the work was expected to be completed by late 2014.
- Subsequent to quarter-end, the company reduced the exercise price of certain January 2012 warrants from $0.88 to $0.40 for a limited period. By October 31, 2013, it had issued 7.75 million shares and received approximately $3.1 million of net proceeds.
- In November 2013, the company completed a private placement of 1.2 million shares at $0.40 per share, generating approximately $0.5 million of net proceeds.
- The company reported that it had resolved previously cited NYSE MKT listing deficiencies as of October 25, 2013.
- As of October 31, 2013, 64.442 million common shares were outstanding, compared with 56.692 million shares outstanding at September 30, 2013, reflecting the subsequent warrant exercises and other issuance activity.
Important Facts for Investors to Verify
- Whether additional financing or licensing proceeds will be required before the company reaches cash-flow breakeven and whether such funding can be obtained without substantial dilution.
- The timing, scope, and economic value of the FioCruz contract amendment and any resulting revenue recognition.
- Execution of the Fraunhofer settlement obligations, including the minimum $3 million of required research and development work through December 31, 2015.
- The company’s ability to generate recurring licensing, collaboration, product, or service revenue, given zero revenue in the current quarter.
- The fully diluted share count, including approximately 20.4 million outstanding warrants and approximately 8.1 million stock options at September 30, 2013, as well as the subsequent warrant exercises.
- The continued applicability of the going-concern disclosure and the company’s projected cash runway under current operating assumptions.